USFDA gives nod for Amphotericin B Liposome Injection

Where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate as well as in the treatment of visceral leishmaniasis

288
USFDA Approval
USFDA Approval

Last Updated on October 17, 2024 by The Health Master

Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, recently received final approval from the US Food & Drug Administration (USFDA) for Amphotericin B Liposome for Injection, 50 mg.

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), AmBisome Liposome for Injection, 50 mg/vial, of Astellas Pharma US, Inc.

As per the statement, the product is expected to be launched by Q4 FY23. The approved product has an estimated market size of around US$ 145 million for the 12 months ending September 2022, according to IQVIA.

As per the release:

Amphotericin B Liposome for Injection is indicated as empirical therapy for presumed fungal infection in febrile, neutropenic patients, treatment of cryptococcal meningitis in HIV-infected patients, treatment of patients with Aspergillus species, Candida species

and/or Cryptococcus species infections refractory to amphotericin B deoxycholate,

or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate as well as in the treatment of visceral leishmaniasis.

In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following the initial clearance of parasites.

USFDA gives approval for Potassium-deficiency drug

USFDA gives final approval for Cyclophosphamide capsules

USFDA gives nod to market this generic Antibiotic Drug

USFDA gives tentative approval for Drospirenone tablets

USFDA approves Ketorolac Tromethamine injection

USFDA gives final approval for Sodium Phenylbutyrate tablets

USFDA issues Form 483 with 10 observations to Aurobindo Pharma

USFDA gives approval for Potassium-deficiency drug

Govt starts drive against misuse of Antibiotics

Bar code or QR code for 300 brands: Govt notifies these drugs under Schedule H2

USFDA gives EIR to Aurobindo Pharma for its AP facility

Maha FDA to take action against bodybuilders involved in misuse of prescription drugs

Altering the contents of formulation without changing brand names

Dr VG Somani gets another three-month extension for his post as DCGI

Govt dissolves Odisha State Pharmacy Council

Latest Notifications regarding Pharmaceuticals

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news